Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...
Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet aimed at treating metabolic disorders, such as obesity. The VENTURE-Oral Dosing Trial is a ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily ... only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements ...
In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...
In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback